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Abstract
Background: Current data on the pattern of parkinsonism and Parkinson's disease in Nigerians are
sparse.
This database was designed to document the clinical profile of PD in Nigerians, and compare this to prior
observations.
Methods: A database of patients presenting to the Neurology out-patients clinic of the Lagos University
Teaching Hospital was established in October 1996. Demographic and clinical data at presentation (disease
stage using Hoehn and Yahr scale; 'off' state severity on the Unified Parkinson's disease Rating Scale) were
documented for patients diagnosed with parkinsonism between October 1996 and December 2006. Cases
were classified as Parkinson's disease or secondary parkinsonism (in the presence of criteria suggestive of
a secondary aetiology).
Results: The hospital frequency of parkinsonism (over a 2-year period, and relative to other neurologic
disorders) was 1.47% (i.e. 20/1360). Of the 124 patients with parkinsonism, 98 (79.0%) had PD, while 26
(21.0%) had secondary parkinsonism. Mean age (SD) at onset of PD (61.5 (10.0) years) was slightly higher
than for secondary parkinsonism (57.5 (14.0) years) (P = 0.10). There was a male preponderance in PD
(3.3 to 1) and secondary parkinsonism (2.7 to 1), while a positive family history of parkinsonism was
present in only 1.02% (1/98) of PD. There was a modestly significant difference in age at onset (SD) of PD
in men (60.3 (10.4)) compared to women (65.2 (7.9)) (T = 2.08; P = 0.04). The frequency of young onset
PD (≤ 50 years) was 16.3% (16/98). The mean time interval from onset of motor symptoms to diagnosis
of PD was 24.6 ± 26.1 months with majority presenting at a median 12 months from onset. On the H&Y
scale, severity of PD at presentation was a median 2.0 (range 1 to 4). PD disease subtype was tremor-
dominant in 31 (31.6%), mixed 54 (55.1%) and akinetic-rigid 14 (14.3%). Hypertension was present as a
co-morbidity in 20 (20.4%), and diabetes in 6 (6.12%).
Conclusions: The clinical profile of PD in Nigerians is similar to that in other populations, but is
characterized by delayed presentation as has been reported in other developing countries. Young-onset
disease occurs but may be less commonly encountered, and frequency of a positive family history is lower
than in western populations.
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Background
Parkinson's disease (PD) is a slowly progressive neurode-
generative movement disorder resulting from selective
loss of nigral dopaminergic neurons of unknown aetiol-
ogy. PD predominantly affects the elderly population, and
is clinically characterized by both motor and non-motor
manifestations. The disease occurs worldwide, with stud-
ies in Africa yielding hospital frequencies of 0.3 to 2.3%
of neurological diseases [1]. In western Nigeria, the prev-
alence rate is between 50 - 90 per 100,000 of the popula-
tion aged above ten years [2,3]. The lower prevalence in
comparison to both the black and Caucasian population
in industrialized western countries such as the United
States of America (USA) has been attributed to possible
genetic, environmental or demographic factors [4].
The pattern of occurrence of parkinsonism (including PD)
in Nigerians was comprehensively reviewed by earlier
authors in Ibadan in 1979 [5], providing a basis for com-
parison with observed patterns globally. Their findings
compared favourably with the earlier reports of Hoehn
and Yahr published 12 years prior and based on cases seen
in the USA [6]. Subsequently, there has been a void in
reports of the pattern of PD observed in sub-Saharan Afri-
can populations in recent years, particularly as the conti-
nent becomes more industrialized. The catchment area of
the Lagos University Teaching Hospital, a tertiary health
institution and referral center for neurological conditions,
includes (but is not limited) to Lagos State in Southwest-
ern Nigeria (a predominantly urban and industrialized
area) and its environs.
This study provides a description of the clinical character-
istics of our cohort of Nigerian PD patients, and provides
a basis for comparison to existing observations, so as to
determine if there has been any appreciable variation
from previously reported patterns.
Methods
A database of patients presenting to the Neurology out-
patients clinic of the Lagos University Teaching Hospital
was established in October 1996. Approval of the study
protocol was obtained from the Health Research and Eth-
ics Committee of the LUTH, and informed consent was
obtained from all patients. Demographic and clinical data
of all consecutively attending patients with parkinsonism
over a ten year period (October 1996 to December 2006)
were systematically documented. The definition of the
syndrome of parkinsonism was based on a combination
of clinical data and presumed aetiology. The diagnosis of
parkinsonism was made on the basis of the presence of at
least three of the four cardinal features i.e. tremors, rigidity,
bradykinesia, and postural or gait abnormality. All patients
diagnosed as PD had all 3 of tremors, rigidity, and brady-
kinesia. The diagnosis of idiopathic parkinsonism (Par-
kinson's disease) was premised on the presence of
parkinsonism without any identifiable secondary cause,
asymmetry at onset, absence of atypical features (e.g. early
prominent dysautonomia, early or preceding cognitive
impairment, cerebellar features, muscle weakness, tempo-
ral relationship to drug or toxin exposure, bilateral symp-
toms at onset, lower-body parkinsonism, otherwise
unexplained corticospinal tract signs), and, in retrospect,
sustained levodopa responsiveness.
The diagnosis of the specific secondary parkinsonism was
based on the constellation of clinical features suggestive
of a secondary aetiology [6-8]. Neuroimaging (brain com-
puterised tomographic scan and magnetic resonance
imaging) was available for 9 cases including the patients
with olivopontocerebellar atrophy (1), hemiparkinson-
ism (1), 3 with vascular parkinsonism secondary to cere-
brovascular disease, and 4 with PD.
A standard proforma was used to document the diagnosis
of PD, personal data (present age and sex) as well as the
patient characteristics (age at onset of the disease, age at
presentation, duration of illness prior to presentation, and
initial symptoms and distribution of symptoms of PD).
The age at onset of PD-related motor symptoms was used
to define age at onset of the disease in this study. Young
onset PD was defined as age at onset ≤ 50 years. A positive
family history of PD was defined as a history of parkinso-
nian features or reported physician's diagnosis of PD in a
first degree relative. The severity at presentation was clas-
sified using the Hoehn and Yahr (H&Y) scale [9,10]. PD
cases presenting after December 2004 were routinely
assessed in the 'off' state at presentation with the Unified
Parkinson's Disease Rating Scale (UPDRS) version 3.0
(11).
Data were analyzed using EPI Info® 2002 statistical soft-
ware. Continuous data are expressed as mean (standard
deviation) (SD), median, and ranges. Mean values were
compared using the Student t test. The X2 test was used to
compare categorical variables which are presented as pro-
portions (frequency %). P < 0.05 was considered as statis-
tically significant.
Results
Hospital frequency of parkinsonism and PD
The hospital frequency of parkinsonism with respect to
other neurologic disorders seen in the outpatient neurol-
ogy clinic of the LUTH was determined by comparing
total number of new referrals with parkinsonism seen
over a two year period (January 2005 to December 2006)
to total number of new outpatients attending the adult
neurology clinic in the same period. The adult neurology
clinic attends to patients aged 12 years and above. In the
two-year period, the total number of new cases of parkin-BMC Neurology 2010, 10:1 http://www.biomedcentral.com/1471-2377/10/1
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sonism was 24 and total number of new referrals was
1360, giving a hospital frequency of 1.76%. The corre-
sponding hospital frequency of PD was 1.47% (i.e. 20/
1360).
Classification of parkinsonism (relative frequencies of PD 
and secondary parkinsonism)
A total of 124 patients fulfilling the diagnostic criteria for
the syndrome of Parkinsonism were seen during the ten-
year period from 1996 to 2006. Of these, 98 (79.0%) had
features compatible with PD, while 26 (21.0%) had sec-
ondary parkinsonism as shown in Table 1.
Comparison of clinical characteristics of PD and secondary 
parkinsonism
The age at onset of symptoms in the 98 PD cases
(mean(SD) 61.5(10.0) years, median 63, range 37 to 77)
was slightly but insignificantly higher than that of the 26
patients with secondary parkinsonism overall (mean(SD)
57.5(14.0)) years, median 61.5, range 22 to 78) (T = 1.66;
P = 0.10) (Table 1). However, the 5 patients with drug-
induced parkinsonism were significantly younger than
those with PD (mean (SD) 46.0(11.3) years, median 45.0,
range 37 to 65) (T = 3.34; P = 0.001).
There was a male preponderance in both idiopathic PD
(male to female ratio 3.3 to 1) and secondary parkinson-
ism (2.7 to 1 overall, 4.25 to 1 for secondary parkinson-
ism excluding drug-induced, and 1 to 1.5 for drug-
induced parkinsonism). A positive family history of par-
kinsonism was present in only 1.02% (1/98) of PD cases
and 0% of secondary parkinsonism. The frequencies of
the presumed secondary aetiologies of parkinsonism are
shown in Table 2.
Clinical characteristics of PD
Age at onset and frequency of young onset PD
There was a modestly significant difference in age at onset
of PD in men (mean(SD) 60.3 (10.4); median 62.0; range
37 to 77) compared to women (mean(SD) 65.2(7.9);
median 68.0; range 41 to 74) (T = 2.08; P = 0.04). The fre-
quency of young onset PD (≤ 50 years) was 16.3% (16/
98), and was higher in men (15/75 i.e. 20%) compared to
women (1/23 i.e. 4.3%) (Fisher exact test; P = 0.06). A
positive family history of PD was present in 1/16 (6.2%)
of the young onset PD, while none of the PD patients with
age at onset above 50 years had a family history of PD.
Disease duration and severity at presentation
The mean (SD) time interval from the onset of motor
symptoms to diagnosis of PD was 24.6 (26.1) months
(men 24.6(28.4); female 24.4(17.2); T = 0.05, P = 0.96)
with most patients presenting at a median 12 months
from onset (range 4 to 156 months).
None of the patients had received a definite diagnosis of
PD prior to specialist consultation. The diagnosis stated in
the referral letter was as follows: neurological disorder (or
neurological symptoms, not otherwise specified) - 40
(40.8%), tremors (cause unknown) - 33 (33.7%), parkin-
sonism - 10 (10.2%), stroke - 10 (10.2%), and osteoar-
thritis - 5 (5.1%).
Median H&Y scale score of PD patients at presentation
was a median 2.0 (range 1 to 4; mean(SD) 2.3(0.8)). The
distribution of PD cases by disease severity at presentation
was as follows: stage 1 - 12 (12.2%), stage 2 - 53 (54.1%),
stage 3 - 29 (29.6%), stage 4 - 4 (4.1%), stage 5 - 0 (0%).
Clinical features of PD cases evaluated between 1996 and 2006
The initial side of onset of the earliest PD-related motor
symptoms in our cases was the right side (60/98 i.e.
61.2%), whereas the left side was the side of onset in 38
cases (38.8%). The upper limb was initially affected in 87
(88.8%) while the lower limb was the initial site in 11
(11.2%). The first motor symptom was reported as trem-
ors in 75 (76.5%), and as stiffness/persistent aching/rigid-
ity in 23 (23.5%). Disease subtype was characterised as
tremor-dominant in 31 (31.6%), mixed in 54 (55.1%)
and akinetic-rigid in 14 (14.3%). Hypertension was






Frequency (%) 98/124 (79.0%) 26/124 (21.0%)
Male (%) 75 (76.5%) 19 (73.1%) RR = 1.04 (95% CI 0.83-1.30)
Female (%) 23 (23.5%) 7 (26.9%)
Male to female ratio 3.3 to 1 2.7 to 1
Mean age (SD) at onset, years 61.5 (10.0) 57.5 (14.0) T = 1.66; P = 0.10
Median age at onset 63 61.5
Age range at onset 37 to 77 22 to 78
Family history of PD in FDR 1 (1.02%) 0 (0%) RR = 1.27 (95% CI 1.16-1.39)
FDR First degree relative
RR Relative risk
CI 95% Confidence IntervalBMC Neurology 2010, 10:1 http://www.biomedcentral.com/1471-2377/10/1
Page 4 of 6
(page number not for citation purposes)
present as a co-morbidity in 20 (20.4%), and diabetes in
6 (6.12%). UPDRS scores were included as part of routine
evaluation of all PD cases in the later years of the study
and are available for 40 consecutively presenting cases
presenting after December 2004. For the 40 cases (median
HY scale 2; mean (SD) 2.3(0.9)), the UPDRS scores (total,
motor and ADL) are shown in Table 3, along with the
summary data of other clinical characteristics of all 98 PD
cases.
Medication use in PD cases
All the 98 PD cases (100%) were placed on levodopa/car-
bidopa 250 mg/25 mg starting at 1/2 tablet (125 mg lev-
odopa/12.5 mg carbidopa) 8 hourly with individualized
upward titration and dose adjustments based on clinical
response in each case. Of these 98, medication utilization
data are available for 75 PD cases still attending the out-
patient clinic as at December 2006 (dropouts due to either
death, relocation or loss to follow-up). All 75 cases
(100%) were on levodopa/carbidopa (LD/CD). The dis-
tribution was as follows: LD/CD monotherapy - 34
(45.3%), LD/CD + dopamine agonist - 21 (28%); LD/CD
+ anticholinergic benztropine - 12 (16%), and LD/CD +
dopamine agonist + anticholinergic benztropine - 8
(10.7%). The mean LD dose (mg/24 hours) (SD) was
605.8(181.8) (range 375 to 1125). The dopamine agonist
used in 28/29 cases was bromocriptine, while only 1 PD
patient was on ropinrole.
Discussion
This study provides a description of the current clinical
profile of PD and secondary parkinsonism as seen over
the last ten years at a tertiary referral centre in South-west-
ern Nigeria. The spectrum of cases encountered may thus
be subject to referral bias, with a tendency to see more
severe or more complex neurological cases. The study
however provides data for comparison with an earlier
report and global perspectives of parkinsonism and PD.
In contrast to the only published report on the clinical
characteristics of parkinsonism in Nigerians from Osun-
tokun and Bademosi [5], PD accounted for a significantly
higher proportion of causes of parkinsonism in the
present study (79% compared to 38%). The current rela-
tive frequency of PD in our study is in keeping with avail-
able literature, which ranks PD as causing approximately
three quarters of all cases of parkinsonism. The apparent
disparity may be accounted for by more recent improve-
ments and streamlining of the diagnostic criteria for PD
and other parkinsonian syndromes in both the clinical
and research arena in contrast to the status at the time of
the earlier report [5,12-14].
Table 2: Aetiologies of secondary parkinsonism in Lagos, Nigeria
Presumed aetiology Number Frequency %
Vascular parkinsonism 9 34.6
Drug-induced parkinsonism 5 19.2
Multiple System Atrophy 4 15.4
Lewy body dementia 3 11.5
Toxin exposure (carbon-monoxide poisoning) 1 3.8
Progressive supranuclear palsy 1 3.8
Hemiparkinsonism - hemiatrophy 1 3.8
Juvenile parkinsonism with dystonia and hemiatrophy 1 3.8
Primary amyloidosis with parkinsonism 1 3.8
* MSA - Shy Drager (autonomic) = 3; MSA - Olivopontocerebellar atrophy = 1
Table 3: Clinical profile of PD at presentation in Nigerians (1996 to 2006)
Clinical characteristic Mean (SD) Median Range
Age at onset of PD in men, years 60.3 (10.4) 62.0 37 - 77
Age at onset of PD in women, years 65.2 (7.9) 68.0 41 - 74
Interval from onset to diagnosis, months 24.6 (26.1) 12.0 4 - 156
Hoehn & Yahr scale 2.3 (0.8) 2.0 1 - 4
UPDRS Total score (n = 40) 57.7 (25.0) 55.5 19 - 128
UPDRS Motor score (n = 40) 41.1 (17.6) 42.0 9 - 87
UPDRS ADL score (n = 40) 13.6 (7.2) 11.0 4 - 36
Total number of PD cases = 98 unless otherwise stated
UPDRS Unified Parkinson's Disease Rating Scale version 3.0
ADL Activities of daily livingBMC Neurology 2010, 10:1 http://www.biomedcentral.com/1471-2377/10/1
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The clinical profile of our patients differed slightly from
that reported in the earlier Nigerian study. First, the mean
age at onset in the present study was 61.5 years, higher
than the 55.6 years reported by Osuntokun et al [5]. Both
studies represent patients seen in the same geographical
region, with both tertiary centres being within two hours'
drive of each other. The increase in age at onset may thus
be an accurate phenomenon akin to that observed by
Hoehn and Yahr in which they found a time trend of
increasing age at onset over decades of study [9]. It has
been documented that as populations age, the age at onset
of PD tends to increase. The male preponderance reported
in the earlier study (ratio 4.5 to 1) was also documented
here, but the magnitude in this study was lower (ratio 3.3
to 1). Although this male predilection appears to be a con-
sistent finding, the precise reason is unknown, and the
possibility of a neuroprotective effect mediated by estro-
gen in women exists [15-17]. Experimental evidence indi-
cates that estrogen may mediate this effect via several
mechanisms including inhibition of dopamine trans-
porter affinity and prevention of entry of neurotoxic
agents into dopaminergic nerve terminals, thereby reduc-
ing nigrostriatal degeneration [17].
Genetic contributions to the aetiology of PD are undisput-
able, with transmission as an autosomal recessive or dom-
inant trait linked to mutations in several genes, including
α-synuclein, parkin, DJ1, leucine-rich repeat kinase
(LRRK) 2, etc [18,19]. Genetic susceptibility appears to be
more apparent (although not exclusive) in young onset
PD compared to persons developing the disease after the
6th decade of life. We found a positive family history of PD
in a first degree relative in only one of our patients who
incidentally had young onset PD starting below age 50.
Young onset PD was documented in 16.3% of our cohort,
with a five-fold higher frequency in men (20%) compared
to women (4.3%). We acknowledge the fact that the
number of PD cases reported here (including only 23
females) is small and may account for the low rates of a
positive family history and gender disparity in frequency
of young-onset PD; our findings are thus subject to further
validation. A preliminary analysis of the genetic contribu-
tions to PD in Nigerians (which included some of the
cases reported in this present study), explored the role of
mutations in LRRK2,  PRKN  and  ATXN3  in apparently
sporadic PD compared to age - and ethnically-matched
controls. The study found that common pathogenic muta-
tions in these genes, previously observed in several popu-
lations, are not a frequent cause of PD in Nigerians [20].
Overall, the clinical profile of PD in Nigerians does not
appear to vary substantially from disease characteristics
reported in other populations. Delayed presentation (and
late referral) are not germaine to this study population
and is one of the challenges encountered in managing PD
in Africa [21]. Poor recognition of the cardinal features of
parkinsonism and of the existence or benefit of available
therapies in alleviating the symptoms and improving the
quality of life of people with PD may contribute to late
referrals. This has further implications as it will delay uti-
lization of disease-modifying strategies which may
become available in the future. Strategies to improve early
recognition and referral include strengthening undergrad-
uate movement disorders curriculum, and improving
public awareness as to the existence, cardinal features, and
treatment options of parkinsonism via the media. The
need for such an approach is strengthened by the
increased likelihood of physicians encountering PD and
other neurodegenerative diseases of the elderly in the
future in developing countries experiencing an epidemio-
logic transition marked by aging of the population.
We acknowledge the methodological limitations of this
study in that follow-up data on the disease course and rate
of progression, and an objective measure of magnitude of
response to levodopa therapy, and mortality data which
would enhance insight into the phenotypy of our PD
cohort are lacking. An earlier published study of a sub-
group of this cohort (28 PD cases and 28 age-matched
controls) initially seen between January and June 1997
and followed up between January and May 2003 (after a
6-year interval) reported a case fatality rate of 25% in PD,
compared to 7.1% in controls [22]. The peculiarity of our
clinical practice scenario, characterized by the availability
of a very narrow spectrum of antiparkinsonian medica-
tions and dosage formulations is reflected in the distribu-
tion of medications used in PD treatment in our cohort.
We also emphasize that this factor would also limit the
conclusiveness of any description of treatment outcomes
in our cohort at the present time.
Conclusion
Our study provides data on the clinical profile of Nigerian
patients with PD and demonstrates that it is similar to that
from other populations, but is characterized by delayed
presentation as has been reported in other developing
countries. Young-onset disease occurs but may be less
commonly encountered, and frequency of a positive fam-
ily history is lower than in western populations.
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